Skip to main content
Premium Trial:

Request an Annual Quote

Also Subvariants

Moderna says that an updated version of its SARS-CoV-2 vaccine led to strong immune responses against the BA.4 and BA.5 Omicron subvariants, the Wall Street Journal reports. Those subvariants, it notes, now make up about a third of COVID-19 cases in the US.

The company previously reported that its bivalent booster vaccine that targets both the original SARS-CoV-2 strain and the Omicron variant triggered even stronger immune response against Omicron than its original vaccine. In the new analysis, they found that the bivalent booster also elicits a strong antibody response to the BA.4 and BA.5 Omicron subvariants that are increasing in circulation.

The Journal says that Moderna plans to provide this data to US regulators as part of its bid to receive authorization for its bivalent booster by August. CBS News adds that Moderna has been manufacturing doses of the bivalent booster in anticipation of that authorization.

Pfizer is similarly developing shots aimed at viral variants, according to the Journal.

Filed under

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.